Literature DB >> 19383313

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Anton Platz1, Suzanne Egyhazi, Ulrik Ringborg, Johan Hansson.   

Abstract

A majority of cutaneous melanomas show activating mutations in the NRAS or BRAF proto-oncogenes, components of the Ras-Raf-Mek-Erk signal transduction pathway. Consistent data demonstrate the early appearance, in a mutually exclusive manner, of these mutations. The purpose of this paper is to summarize the literature on NRAS and BRAF activating mutations in melanoma tumors with respect to available data on histogenetic classification as well as body site and presumed UV-exposure. Common alterations of the signal transducing network seem to represent molecular hallmarks of cutaneous melanomas and therefore should continue to strongly stimulate design and testing of targeted molecular interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19383313      PMCID: PMC5543839          DOI: 10.1016/j.molonc.2007.12.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  88 in total

1.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

Authors:  A Demunter; M Stas; H Degreef; C De Wolf-Peeters; J J van den Oord
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

2.  Detection of B-RAF and N-RAS mutations in human melanoma.

Authors:  James S Goydos; Barbara Mann; Hyunjin J Kim; Emmanuel M Gabriel; Janivette Alsina; F Joseph Germino; Weichung Shih; David H Gorski
Journal:  J Am Coll Surg       Date:  2005-03       Impact factor: 6.113

Review 3.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Authors:  Thomas Hocker; Hensin Tsao
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

4.  High BRAF mutation frequency does not characterize all melanocytic tumor types.

Authors:  Gerald Saldanha; David Purnell; Alan Fletcher; Linda Potter; Angela Gillies; J Howard Pringle
Journal:  Int J Cancer       Date:  2004-09-20       Impact factor: 7.396

5.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

6.  High frequency of BRAF mutations in nevi.

Authors:  Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer
Journal:  Nat Genet       Date:  2002-11-25       Impact factor: 38.330

7.  V599EB-RAF is an oncogene in melanocytes.

Authors:  Claudia Wellbrock; Lesley Ogilvie; Douglas Hedley; Maria Karasarides; Jan Martin; Dan Niculescu-Duvaz; Caroline J Springer; Richard Marais
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

8.  Absence of BRAF mutations in UV-protected mucosal melanomas.

Authors:  R H Edwards; M R Ward; H Wu; C A Medina; M S Brose; P Volpe; S Nussen-Lee; H M Haupt; A M Martin; M Herlyn; S R Lessin; B L Weber
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  83 in total

1.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Authors:  Patrick A Oberholzer; Damien Kee; Piotr Dziunycz; Antje Sucker; Nyam Kamsukom; Robert Jones; Christine Roden; Clinton J Chalk; Kristin Ardlie; Emanuele Palescandolo; Adriano Piris; Laura E MacConaill; Caroline Robert; Günther F L Hofbauer; Grant A McArthur; Dirk Schadendorf; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  BRAF mutations in non-small cell lung cancer.

Authors:  Peter P Luk; Bing Yu; Chiu Chin Ng; Belinda Mercorella; Christina Selinger; Trina Lum; Steven Kao; Sandra A O'Toole; Wendy A Cooper
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence.

Authors:  Charlotte Lemech; Jeffrey Infante; Hendrik-Tobias Arkenau
Journal:  Ther Adv Med Oncol       Date:  2012-03       Impact factor: 8.168

4.  Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells.

Authors:  Gaurav Kaushik; Satish Ramalingam; Dharmalingam Subramaniam; Parthasarthy Rangarajan; Piero Protti; Prabhu Rammamoorthy; Shrikant Anant; Joshua M V Mammen
Journal:  Am J Surg       Date:  2012-12       Impact factor: 2.565

5.  Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.

Authors:  Niloofar Fadaki; Servando Cardona-Huerta; Lea Martineau; Suresh Thummala; Shih-Tsung Cheng; Steve R Bunker; Richard Garcia-Kennedy; Wei Wang; David Minor; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  BMJ Case Rep       Date:  2012-10-22

Review 6.  Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.

Authors:  Philip Eliades; Keith T Flaherty; Hensin Tsao
Journal:  Melanoma Manag       Date:  2015-05-18

7.  MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations.

Authors:  Sisheng Liu; Jinpeng Liu; Yanqi Xie; Tingting Zhai; Eugene W Hinderer; Arnold J Stromberg; Nathan L Vanderford; Jill M Kolesar; Hunter N B Moseley; Li Chen; Chunming Liu; Chi Wang
Journal:  Bioinformatics       Date:  2021-06-09       Impact factor: 6.937

Review 8.  Emerging tale of UPR and cancer: an essentiality for malignancy.

Authors:  Younis Mohammad Hazari; Arif Bashir; Ehtisham Ul Haq; Khalid Majid Fazili
Journal:  Tumour Biol       Date:  2016-09-14

Review 9.  Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment.

Authors:  Mohamed Hassan; Denis Selimovic; Matthias Hannig; Youssef Haikel; Robert T Brodell; Mossaad Megahed
Journal:  World J Exp Med       Date:  2015-11-20

10.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.